Cargando…

Efficacy and safety of Sofosbuvir-containing regimens in patients co-infected with chronic hepatitis C virus and human immunodeficiency virus: a meta-analysis

BACKGROUND: The treatment of hepatitis C virus (HCV) in HCV/human immunodeficiency virus (HIV) co-infected patients remains complex. This present meta-analysis evaluated the efficacy and safety of Sofosbuvir (SOF) for treatment in HCV/HIV co-infected patients using the most recent and available data...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Guotao, Zang, Ke, Zhang, Guoqiang, Zhu, Danyan, Deng, Xiaozhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775578/
https://www.ncbi.nlm.nih.gov/pubmed/29351766
http://dx.doi.org/10.1186/s12985-018-0934-6
_version_ 1783293939265044480
author Li, Guotao
Zang, Ke
Zhang, Guoqiang
Zhu, Danyan
Deng, Xiaozhao
author_facet Li, Guotao
Zang, Ke
Zhang, Guoqiang
Zhu, Danyan
Deng, Xiaozhao
author_sort Li, Guotao
collection PubMed
description BACKGROUND: The treatment of hepatitis C virus (HCV) in HCV/human immunodeficiency virus (HIV) co-infected patients remains complex. This present meta-analysis evaluated the efficacy and safety of Sofosbuvir (SOF) for treatment in HCV/HIV co-infected patients using the most recent and available data. METHODS: A systematic search of the published data was conducted in PubMed Medline, EMBASE and Cochrane databases. Eligible studies were clinical trials, case-control studies or prospective cohort studies aiming at assessing the efficacy and safety of the SOF-containing regimens in patients co-infected with HCV and HIV. Heterogeneity of results was assessed and a pooled analysis was performed using random effects model with maximum likelihood estimate and 95% confidence intervals (95%CI). Subgroup analysis and assessment of publication bias through Egger’s test were also performed. STATA 13.0 software was used to analyze the data. RESULTS: Seven studies (n = 1167 co-infected patients) were included in this analysis. The pooled estimate of sustained virological response at 12 weeks (SVR12) was 94.0% (95%CI: 92.0%–95.0%). Subgroup analysis showed that the treatment-naïve patients had higher SVR12 compared with patients that were treated before (χ(2) = 21.39, P < 0.01). The pooled incidence of any adverse events (AEs) was 79.6% (95%CI: 77.1%–82.1%). Publication bias did not exist. CONCLUSION: The results of this study showed that the treatment response of SOF-containing regimens in patients co-infected with HIV and HCV was satisfied. Attention should be paid to the high rates of AEs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12985-018-0934-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5775578
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57755782018-01-31 Efficacy and safety of Sofosbuvir-containing regimens in patients co-infected with chronic hepatitis C virus and human immunodeficiency virus: a meta-analysis Li, Guotao Zang, Ke Zhang, Guoqiang Zhu, Danyan Deng, Xiaozhao Virol J Research BACKGROUND: The treatment of hepatitis C virus (HCV) in HCV/human immunodeficiency virus (HIV) co-infected patients remains complex. This present meta-analysis evaluated the efficacy and safety of Sofosbuvir (SOF) for treatment in HCV/HIV co-infected patients using the most recent and available data. METHODS: A systematic search of the published data was conducted in PubMed Medline, EMBASE and Cochrane databases. Eligible studies were clinical trials, case-control studies or prospective cohort studies aiming at assessing the efficacy and safety of the SOF-containing regimens in patients co-infected with HCV and HIV. Heterogeneity of results was assessed and a pooled analysis was performed using random effects model with maximum likelihood estimate and 95% confidence intervals (95%CI). Subgroup analysis and assessment of publication bias through Egger’s test were also performed. STATA 13.0 software was used to analyze the data. RESULTS: Seven studies (n = 1167 co-infected patients) were included in this analysis. The pooled estimate of sustained virological response at 12 weeks (SVR12) was 94.0% (95%CI: 92.0%–95.0%). Subgroup analysis showed that the treatment-naïve patients had higher SVR12 compared with patients that were treated before (χ(2) = 21.39, P < 0.01). The pooled incidence of any adverse events (AEs) was 79.6% (95%CI: 77.1%–82.1%). Publication bias did not exist. CONCLUSION: The results of this study showed that the treatment response of SOF-containing regimens in patients co-infected with HIV and HCV was satisfied. Attention should be paid to the high rates of AEs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12985-018-0934-6) contains supplementary material, which is available to authorized users. BioMed Central 2018-01-19 /pmc/articles/PMC5775578/ /pubmed/29351766 http://dx.doi.org/10.1186/s12985-018-0934-6 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Li, Guotao
Zang, Ke
Zhang, Guoqiang
Zhu, Danyan
Deng, Xiaozhao
Efficacy and safety of Sofosbuvir-containing regimens in patients co-infected with chronic hepatitis C virus and human immunodeficiency virus: a meta-analysis
title Efficacy and safety of Sofosbuvir-containing regimens in patients co-infected with chronic hepatitis C virus and human immunodeficiency virus: a meta-analysis
title_full Efficacy and safety of Sofosbuvir-containing regimens in patients co-infected with chronic hepatitis C virus and human immunodeficiency virus: a meta-analysis
title_fullStr Efficacy and safety of Sofosbuvir-containing regimens in patients co-infected with chronic hepatitis C virus and human immunodeficiency virus: a meta-analysis
title_full_unstemmed Efficacy and safety of Sofosbuvir-containing regimens in patients co-infected with chronic hepatitis C virus and human immunodeficiency virus: a meta-analysis
title_short Efficacy and safety of Sofosbuvir-containing regimens in patients co-infected with chronic hepatitis C virus and human immunodeficiency virus: a meta-analysis
title_sort efficacy and safety of sofosbuvir-containing regimens in patients co-infected with chronic hepatitis c virus and human immunodeficiency virus: a meta-analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775578/
https://www.ncbi.nlm.nih.gov/pubmed/29351766
http://dx.doi.org/10.1186/s12985-018-0934-6
work_keys_str_mv AT liguotao efficacyandsafetyofsofosbuvircontainingregimensinpatientscoinfectedwithchronichepatitiscvirusandhumanimmunodeficiencyvirusametaanalysis
AT zangke efficacyandsafetyofsofosbuvircontainingregimensinpatientscoinfectedwithchronichepatitiscvirusandhumanimmunodeficiencyvirusametaanalysis
AT zhangguoqiang efficacyandsafetyofsofosbuvircontainingregimensinpatientscoinfectedwithchronichepatitiscvirusandhumanimmunodeficiencyvirusametaanalysis
AT zhudanyan efficacyandsafetyofsofosbuvircontainingregimensinpatientscoinfectedwithchronichepatitiscvirusandhumanimmunodeficiencyvirusametaanalysis
AT dengxiaozhao efficacyandsafetyofsofosbuvircontainingregimensinpatientscoinfectedwithchronichepatitiscvirusandhumanimmunodeficiencyvirusametaanalysis